Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncology Institute Inc. is poised for significant financial growth as its partnership with Helios is expected to enhance margins, transitioning to a more favorable cost structure in 2026 and 2027. With an anticipated return to margins of 12%-15% as contracts mature and increasing focus on value-based care, the company is well-positioned for sustainable earnings growth, which is likely to drive stock performance over time. Furthermore, the robust expected growth in dispensing revenue, particularly following the establishment of a new pharmacy in California and the elimination of the DIR fee, supports a healthier profitability profile and increased margin visibility moving forward.

Bears say

The Oncology Institute Inc. has experienced contract losses in 2024, adversely affecting gross margins, and a series of new contracts launching later in 2024 and early 2025 are anticipated to exert additional pressure as they scale. The company’s revenue growth from patient services is likely constrained, with trends indicating flat or low single-digit growth, significantly lagging behind the industry average of 11-14%. Furthermore, the business faces potential challenges from increased drug prices and changes in payer partnerships, which could further compress margins and impede the company’s ability to achieve break-even EBITDA by late 2025.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.